InvestorsHub Logo
Post# of 252107
Next 10
Followers 11
Posts 2370
Boards Moderated 0
Alias Born 06/08/2010

Re: jaybe post# 178018

Friday, 05/16/2014 12:24:32 PM

Friday, May 16, 2014 12:24:32 PM

Post# of 252107
TGTX/BIC/Proof-of-Concept,Etc.

Well jaybe,

You raise a lot of issues, but I'll do my best to respond in terms of what I believe are the top priorities(for a stockholder):

1) I didn’t say it(TGR-1202) would be BIC, only that I believe this data(combined with the favorable tox profile) suggests it has an excellent shot-yet to be proven one way or the other.

2) I would disagree with you that a BIC PI3K drug(with a favorable tox profile) may not have a market. I don’t think there are many people in the B-cell therapy sector that would deny the value of such in a variety of combos.

3) Although TGTXs combo final results may be a few years off, I think more importantly, we should be in possession of proof of concept information for both drugs in 2 combo therapies, in addition to longer term(convincing) mono therapy data for both, by the end of this year(see timelines listed in latest slide presentation below):

2014 Milestones (see pg23 of PDF linked below)

1H 2014 Determine optimal dosing for TGR-1202 as single agent

Enroll Ph. 2 TG-1101 + Ibrutinib in CLL and MCL

Enroll Ph. 2 TG-1101 + TGR-1202 in B-cell Malignancies

Q2 2014 ASCO - Present updated single agent data for TG-1101 & TGR1202

EHA - Present prelim combo data for TG-1101 + Ibrutinib (June, 2014)

Q3 2014 Pan-Pacific - Present prelim combo data for TG-1101 + TGR-1202 (July, 2014)

2H 2014 Commence combination registration trial(s)

Q4 2014 Present updated combo data and single agent TGR-1202 data

http://files.shareholder.com/downloads/MHA/3008734518x0x753325/1106d1c2-a7ec-49cd-bb0a-dc8471e1f2b3/TG_Therapeutics_Corporate_Presentaton_May_2014_DB_Conference.pdf

At that point, assuming the data holds up and progresses as I think it will(if not well before>>>like now!) relative value issues will certainly come into play, and a company with a measly Ent. Value of approx 120ml with 2 very active drugs that it can use in combo, either by itself, or with those of other companies, will come into bold relief and a very significant revaluation should occur.

Remember, the first 2 combo preliminary results are due within the next 2 months...

Best regards,

bw

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.